Sample Distribution, Processing, Banking and Database

$180,333P01FY2008CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Linked publications & trials

Paper 39251642 Paper 39102652 Paper 37909388 Paper 37732181 Paper 37679459 Paper 37046084 Paper 36108743 Paper 34875037 Paper 34698806 Paper 34663986 Paper 34568833 Paper 34342642 Paper 34027417 Paper 33654306 Paper 33408186 Paper 33208943 Paper 33054119 Paper 32961550 Paper 32150605 Paper 31043423 Paper 30957058 Paper 30385546 Paper 30064974 Paper 29954749 Paper 28985529 Paper 28264936 Paper 26726291 Paper 26512454 Paper 26438514 Paper 26131937 Paper 25972343 Paper 25550361 Paper 25224413 Paper 25126716 Paper 24616378 Paper 24414704 Paper 24292625 Paper 23863123 Paper 23841653 Paper 23790799 Paper 23763917 Paper 23708912 Paper 23660859 Paper 23487027 Paper 23329810 Paper 22869879 Paper 22826139 Paper 22627765 Paper 22569880 Paper 22517119 Paper 22329458 Paper 21943668 Paper 21858090 Paper 21714648 Paper 21537048 Paper 21527522 Paper 21360576 Paper 21241896 Paper 21239815 Paper 21220589 Paper 21082921 Paper 21068437 Paper 20882045 Paper 20737576 Paper 20679526 Paper 20658546 Paper 20525753 Paper 20359628 Paper 20215543 Paper 20209609 Paper 20162709 Paper 20038729 Paper 19894763 Paper 19795507 Paper 19778854 Paper 19691096 Paper 19571318 Paper 19509174 Paper 19387468 Paper 19336447 Paper 19326367 Paper 19255975 Paper 18931345 Paper 18841054 Paper 18835035 Paper 18798533 Paper 18725933 Paper 18623376 Paper 18548103 Paper 18523155 Paper 18266895 Paper 18259954 Paper 18245532 Paper 18079733 Paper 18064648 Paper 18053070 Paper 17634552 Paper 17363514 Paper 17332327 Paper 17192064

Abstract

The Sample and Molecular Core (Core B) has the following functions: 1. Develop and maintain a repository of blood and bone marrow specimens, including intact cells, serum, cellular DMA, RNA, and protein, from patients with MDS receiving care or evaluation at M.D. Anderson Cancer Center. 2. Distribute samples from MDS patients and normal "controls" to MDS P01 investigators. 3. Maintain a comprehensive, prospective, interactive sample database showing type (at diagnosis, at AML progression etc) and characteristics (DNA, RNA etc) of available MDS samples and of their subsequent disposition. 4. Facilitate intra- and extra- MDS P01 collaborations through sharing of blood and marrow resources. 5. Ascertain the incidence of NRAS, KRAS2, and PTPN11 mutations in patients at diagnosis and every 3 months thereafter. 6. Evaluate the possibility that mutations in PTPN11, RAS, and FLT3 can be used to quantify disease burden in MDS. 7. Measure biochemical endpoints of targeted therapeutics (in particular R115777) and correlate these pharmacodynamic data with responses to therapy given in Project 1.

View original record on NIH RePORTER →